591 related articles for article (PubMed ID: 25096692)
1. Genetic variants associated with phenytoin-related severe cutaneous adverse reactions.
Chung WH; Chang WC; Lee YS; Wu YY; Yang CH; Ho HC; Chen MJ; Lin JY; Hui RC; Ho JC; Wu WM; Chen TJ; Wu T; Wu YR; Hsih MS; Tu PH; Chang CN; Hsu CN; Wu TL; Choon SE; Hsu CK; Chen DY; Liu CS; Lin CY; Kaniwa N; Saito Y; Takahashi Y; Nakamura R; Azukizawa H; Shi Y; Wang TH; Chuang SS; Tsai SF; Chang CJ; Chang YS; Hung SI; ;
JAMA; 2014 Aug; 312(5):525-34. PubMed ID: 25096692
[TBL] [Abstract][Full Text] [Related]
2. Association of CYP2C9*3 with phenytoin-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: A systematic review and meta-analysis.
Wu X; Liu W; Zhou W
J Clin Pharm Ther; 2018 Jun; 43(3):408-413. PubMed ID: 29274302
[TBL] [Abstract][Full Text] [Related]
3. Association of HLA-B*15:13 and HLA-B*15:02 with phenytoin-induced severe cutaneous adverse reactions in a Malay population.
Chang CC; Ng CC; Too CL; Choon SE; Lee CK; Chung WH; Hussein SH; Lim KS; Murad S
Pharmacogenomics J; 2017 Mar; 17(2):170-173. PubMed ID: 26927288
[TBL] [Abstract][Full Text] [Related]
4. Genetic factors associated with severe cutaneous adverse reactions.
Lozano R
JAMA; 2014 Nov; 312(20):2165-6. PubMed ID: 25423224
[No Abstract] [Full Text] [Related]
5. Genetic factors associated with severe cutaneous adverse reactions--reply.
Chung WH; Hung SI
JAMA; 2014 Nov; 312(20):2166. PubMed ID: 25423226
[No Abstract] [Full Text] [Related]
6. Associations between HLA class I and cytochrome P450 2C9 genetic polymorphisms and phenytoin-related severe cutaneous adverse reactions in a Thai population.
Tassaneeyakul W; Prabmeechai N; Sukasem C; Kongpan T; Konyoung P; Chumworathayi P; Tiamkao S; Khunarkornsiri U; Kulkantrakorn K; Saksit N; Nakkam N; Satapornpong P; Vannaprasaht S; Sangviroon A; Mahasirimongkol S; Wichukchinda N; Rerkpattanapipat T; Tassaneeyakul W
Pharmacogenet Genomics; 2016 May; 26(5):225-34. PubMed ID: 26928377
[TBL] [Abstract][Full Text] [Related]
7. An update on CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects.
Chang WC; Hung SI; Carleton BC; Chung WH
Expert Opin Drug Metab Toxicol; 2020 Aug; 16(8):723-734. PubMed ID: 32510242
[TBL] [Abstract][Full Text] [Related]
8. Genotype-phenotype association between HLA and carbamazepine-induced hypersensitivity reactions: strength and clinical correlations.
Hsiao YH; Hui RC; Wu T; Chang WC; Hsih MS; Yang CH; Ho HC; Chang YG; Chen MJ; Lin JY; Chen DP; Chang PY; Wu TL; Hung SI; Chung WH
J Dermatol Sci; 2014 Feb; 73(2):101-9. PubMed ID: 24268988
[TBL] [Abstract][Full Text] [Related]
9. Association of HLA genotypes with phenytoin induced severe cutaneous adverse drug reactions in Thai children.
Manuyakorn W; Likkasittipan P; Wattanapokayakit S; Suvichapanich S; Inunchot W; Wichukchinda N; Khongkhatithuml C; Thampratankul L; Kamchaisatian W; Benjaponpitak S; Mahasirimongkol S
Epilepsy Res; 2020 May; 162():106321. PubMed ID: 32272329
[TBL] [Abstract][Full Text] [Related]
10. Genetic and clinical risk factors associated with phenytoin-induced cutaneous adverse drug reactions in Thai population.
Sukasem C; Sririttha S; Tempark T; Klaewsongkram J; Rerkpattanapipat T; Puangpetch A; Boongird A; Chulavatnatol S
Pharmacoepidemiol Drug Saf; 2020 May; 29(5):565-574. PubMed ID: 32134161
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia.
Ding WY; Lee CK; Choon SE
Int J Dermatol; 2010 Jul; 49(7):834-41. PubMed ID: 20618508
[TBL] [Abstract][Full Text] [Related]
12. HLA-A*24:02 as a common risk factor for antiepileptic drug-induced cutaneous adverse reactions.
Shi YW; Min FL; Zhou D; Qin B; Wang J; Hu FY; Cheung YK; Zhou JH; Hu XS; Zhou JQ; Zhou LM; Zheng ZZ; Pan J; He N; Liu ZS; Hou YQ; Lim KS; Ou YM; Hui-Ping Khor A; Ng CC; Mao BJ; Liu XR; Li BM; Kuan YY; Yi YH; He XL; Deng XY; Su T; Kwan P; Liao WP
Neurology; 2017 Jun; 88(23):2183-2191. PubMed ID: 28476759
[TBL] [Abstract][Full Text] [Related]
13. Presence of the HLA-A*3101 allele in a familial case of drug reaction with eosinophilia and systemic symptoms, secondary to carbamazepine.
Anjum N; Polak ME; Ardern-Jones M; Cooper HL
Clin Exp Dermatol; 2014 Apr; 39(3):307-9. PubMed ID: 24635066
[TBL] [Abstract][Full Text] [Related]
14. Impact of the HLA-B(*)58:01 Allele and Renal Impairment on Allopurinol-Induced Cutaneous Adverse Reactions.
Ng CY; Yeh YT; Wang CW; Hung SI; Yang CH; Chang YC; Chang WC; Lin YJ; Chang CJ; Su SC; Fan WL; Chen DY; Wu YJ; Tian YC; Hui RC; Chung WH;
J Invest Dermatol; 2016 Jul; 136(7):1373-1381. PubMed ID: 26996548
[TBL] [Abstract][Full Text] [Related]
15. A candidate gene study of antiepileptic drug tolerability and efficacy identifies an association of CYP2C9 variants with phenytoin toxicity.
Depondt C; Godard P; Espel RS; Da Cruz AL; Lienard P; Pandolfo M
Eur J Neurol; 2011 Sep; 18(9):1159-64. PubMed ID: 21338443
[TBL] [Abstract][Full Text] [Related]
16. Influence of genetic and non-genetic factors on phenytoin-induced severe cutaneous adverse drug reactions.
Yampayon K; Sukasem C; Limwongse C; Chinvarun Y; Tempark T; Rerkpattanapipat T; Kijsanayotin P
Eur J Clin Pharmacol; 2017 Jul; 73(7):855-865. PubMed ID: 28391407
[TBL] [Abstract][Full Text] [Related]
17. Genetic polymorphism of cytochrome P450 2C9 in diphenylhydantoin-induced cutaneous adverse drug reactions.
Lee AY; Kim MJ; Chey WY; Choi J; Kim BG
Eur J Clin Pharmacol; 2004 May; 60(3):155-9. PubMed ID: 15024534
[TBL] [Abstract][Full Text] [Related]
18. Whole genome sequencing identifies genetic variants associated with co-trimoxazole hypersensitivity in Asians.
Wang CW; Tassaneeyakul W; Chen CB; Chen WT; Teng YC; Huang CY; Sukasem C; Lu CW; Lee YS; Choon SE; Nakkam N; Hui RC; Huang YH; Chang YC; Lin YY; Chang CJ; Chiu TM; Chantratita W; Konyoung P; Lee CN; Klaewsongkram J; Rerkpattanapipat T; Amornpinyo W; Saksit N; Rerknimitr P; Huang YH; Lin SH; Hsu CK; Chan CC; Lin YJ; Hung SI; Chung WH;
J Allergy Clin Immunol; 2021 Apr; 147(4):1402-1412. PubMed ID: 32791162
[TBL] [Abstract][Full Text] [Related]
19. Clinical relevance of genetic polymorphism in CYP2C9 gene to pharmacodynamics and pharmacokinetics of phenytoin in epileptic patients: validatory pharmacogenomic approach to pharmacovigilance.
Kousar S; Wafai ZA; Wani MA; Jan TR; Andrabi KI
Int J Clin Pharmacol Ther; 2015 Jul; 53(7):504-16. PubMed ID: 25943175
[TBL] [Abstract][Full Text] [Related]
20. Phenobarbital-induced severe cutaneous adverse drug reactions are associated with CYP2C19*2 in Thai children.
Manuyakorn W; Siripool K; Kamchaisatian W; Pakakasama S; Visudtibhan A; Vilaiyuk S; Rujirawat T; Benjaponpitak S
Pediatr Allergy Immunol; 2013 May; 24(3):299-303. PubMed ID: 23551241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
